Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 34 % of short-term debt in 2025; threshold 65 %.
-
Legal situation KBO
Vrijwillige ontbinding – vereffening according to the CBE.
Financials
Financial year 2025
3DDD PHARMA from Hasselt, company number BE0452718497, closed financial year 2025 with a result of € -123 after tax. For that financial year 3DDD PHARMA recorded a gross margin of € -1,418 and equity of € -3 million. Compared with financial year 2024, the result moved from € -112 to € -123. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 21, 2026.
€ -3 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -123
▼ 9 % more loss than in 2024
Profit after tax over the fiscal year.
€ 676,936
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -4.9 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 21,390
Supplier invoices still open on the last day of the fiscal year.
€ 2 million
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -1,752 | € -1,959 | € -1,312 | € -1,418 | ▼ € 106 |
| Profit after taxes | € -1,944 | € -1,585 | € -112 | € -123 | ▼ € 11 |
| Equity | € -2,986,521 | € -2,988,105 | € -2,988,218 | € -2,988,341 | |
| Total debts | € 3,300,797 | € 3,300,797 | € 3,300,797 | € 3,300,797 | |
| Cash | € 680,715 | € 678,965 | € 676,421 | € 676,936 | |
| Retained profit | € -4,870,821 | € -4,872,405 | € -4,872,518 | € -4,872,641 | |
| Balance sheet total | € 691,897 | € 690,312 | € 690,200 | € 690,077 |
Key figures of 3DDD PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to 3DDD PHARMA?
What happened at 3DDD PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
3DDD PHARMA is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.
- New annual accounts for financial year 2025: loss of € 123. filed late Source: NBB ↗
- New establishment in Hasselt. KBO
- Start of the company according to the CBE. KBO
In short
From € 1,944 loss in 2022 to € 123 loss in 2025.
A new publication or filing at 3DDD PHARMA? We notify you, reason included.
Follow 3DDD PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Assimco comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
3DDD PHARMABehind 3DDD PHARMA are Ilse Roox and Bert Vandenreyt. The shares are held by Assimco (15%).
Directors
According to the 2025 annual accounts
Ilse Roox
Liquidator
Shareholders
15%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kempische steenweg 301 box 1
3500 Hasselt
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0452.718.497
- VAT number
- BE 0452.718.497
- Registered office
- Kempische steenweg 301 bus 1, 3500 Hasselt
- Names & denominations
- 3DDD PHARMA · 3DDD
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 19 May 1994
- Peppol
- Not registered